AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
New data: Taxotere/carboplatin as effective and less neurotoxic than standard therapy.(Brief Article)(Statistical Data Included)
2002 JUL 11 - (NewsRx.com & NewsRx.net) -- The anticancer drug combination of Taxotere (docetaxel) and carboplatin demonstrated less neurotoxicity and was equally effective as the standard treatment of paclitaxel and carboplatin when used as first-line treatment in patients with advanced ovarian cancer, according to data presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
Using the ovarian-specific Quality of Life questionnaire, EORTC QLQ-OV28, patients treated with Taxotere/carboplatin reported significantly less joint pain and muscular tenderness (33% vs. 48%) than those treated with paclitaxel/carboplatin (p
In other data presented, the two-drug combinations were shown to be similarly effective. Median progression-free survival is 15.1 months in the Taxotere/carboplatin arm and 15.4 months in the paclitaxel/carboplatin arm. At 24 months, the survival rate is 65.4% for Taxotere/carboplatin patients and 69.8% for the paclitaxel/carboplatin group. This study was one of the largest international studies in advanced ovarian cancer ever conducted. Of the 1077 patients randomized at the start of the study, 1074 are available for survival comparison. The median follow-up of the surviving patients is 23 months, with 95% followed for at least 17 months.
"This analysis confirms that the Taxotere/carboplatin combination is a less neurotoxic alternative as first-line chemotherapy in ovarian cancer to the current standard of treatment, which is important because neurotoxicity can interfere with treatment in many patients" said Paul A. Vasey, MD, lead investigator for the Scottish Gynaecological Cancer Trials Group (SGCTG) and medical oncologist at the Cancer Research UK Clinical Trials Unit at Beatson Oncology Center in Glasgow. "Patients in the Taxotere/carboplatin arm received an equally effective drug with markedly less significant symptoms of neurotoxicity than those treated with paclitaxel/carboplatin and thus this combination now can be considered an alternative standard of care."
Severe neurotoxicity can impair a patient's quality of life, causing progressive pain and numbness in the extremities, leading in some ...
- TAXOTERE(R) (docetaxel) SHOWS HIGH ANTI-TUMOR ACTIVITY IN ADVANCED OVARIAN...
- Press release article from: PR Newswire May 17, 1994 700+ words
...35 percent response rate with Taxotere in patients with advanced ovarian cancer who failed the standard platinum...neurological symptoms were mild. Taxotere: A New Treatment for Ovarian Cancer Taxotere belongs to a unique class of anti...
- NEW ANTICANCER AGENT, TAXOTERE (DOCETAXEL), DEMONSTRATES EFFICACY IN OVARIAN...
- Press release article from: PR Newswire January 27, 1996 700+ words
...anticancer agent, Taxotere(R) (docetaxel...treatment of advanced ovarian cancer, according to...treatment of ovarian cancer," said Dr...high activity of Taxotere seen in these...treatment of ovarian cancer in the future...
- More Than 200 Abstracts on Taxotere(R) Included in the Proceedings Of The...
- Press release article from: PR Newswire May 10, 2001 700+ words
...chemotherapy agent Taxotere(R) (docetaxel...breast cancer, ovarian cancer and non-small...of the study. Ovarian Cancer Paul A. Vasey...combination of Taxotere and carboplatin...IV epithelial ovarian cancer. The results...
- BACKGROUNDER: TAXOTERE (DOCETAXEL) RE: FDA APPROVAL TODAY OF TAXOTERE/XELODA...
- Press release article from: PR Newswire September 10, 2001 700+ words
...cancer (NSCLC) who received Taxotere and platinum lived significantly...that the combination of Taxotere and carboplatin appears...for patients with advanced ovarian cancer. These are just two of the several Taxotere studies presented in May...
- TAXOTERE (R) (DOCETAXEL) SHOWS OVERALL RESPONSE RATES OF MORE THAN 50 PERCENT...
- Press release article from: PR Newswire November 15, 1993 700+ words
...U.S.-based study of Taxotere(R), Dr. Peter Ravdin...blocked in most patients. Taxotere(R) is a new antitumor...soft-tissue sarcomas, ovarian cancer, melanoma and pancreatic cancer. Taxotere(R) has been found to...
- STUDIES SHOW TAXOTERE(R) IS ACTIVE IN OVARIAN AND PANCREATIC CANCER
- Press release article from: PR Newswire March 16, 1994 700+ words
...France show that Taxotere (R) (docetaxel...response rate with Taxotere was shown in...with advanced ovarian cancer and a 28% response...patients with ovarian cancer who were previously...hour infusion of Taxotere every three weeks...
- Taxol and taxotere: from yew tree to tumour cell.
- Magazine article from: Chemistry and Industry Joel, Simon P. March 7, 1994 700+ words
...promising activity in breast and ovarian cancer The development of any new...closely related compound, taxotere, which entered clinical trials...1990. Structure Taxol and taxotere are both made up of a complex...differences between taxol and taxotere at position C'3 and C10...
- Yew needles join the cancer battle. (taxotere drug derived from European yew...
- Magazine article from: Science News January 9, 1993 700+ words
...colleagues studied the safety of taxotere by giving varying amounts...that at very high doses of taxotere, cancer patients suffered...Although not designed to assess taxotere's efficacy, the study found...six of the 10 women who had ovarian cancer. The team also reported a...
